| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nienke R Biermasz, Sjoerd W van Thiel, Alberto M Pereira, Hendrieke C Hoftijzer, Albert M van Hemert, Jan W A Smit, Johannes A Romijn, Ferdinand Roelfsem. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. The Journal of clinical endocrinology and metabolism. vol 89. issue 11. 2004-12-02. PMID:15531483. |
in conclusion, patients cured after treatment for acromegaly have a persistently decreased quality of life despite long-term biochemical cure of gh excess. |
2004-12-02 |
2023-08-12 |
Not clear |
| Helen E Turner, Viv A Thornton-Jones, John A H Was. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clinical endocrinology. vol 61. issue 2. 2004-11-08. PMID:15272918. |
the aim of our study was to perform a prospective systematic study to determine whether extending the interval between doses of lar allows maintenance of 'safe' gh in selected patients with acromegaly. |
2004-11-08 |
2023-08-12 |
Not clear |
| A Colao, G Vitale, R Pivonello, A Ciccarelli, C Di Somma, G Lombard. The heart: an end-organ of GH action. European journal of endocrinology. vol 151 Suppl 1. 2004-10-15. PMID:15339252. |
on the other hand, the chronic overproduction of gh and igf-i in acromegaly leads to the development of a specific cardiomyopathy. |
2004-10-15 |
2023-08-12 |
Not clear |
| M Maamra, J J Kopchick, C J Strasburger, R J M Ros. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. The Journal of clinical endocrinology and metabolism. vol 89. issue 9. 2004-10-07. PMID:15356058. |
pegvisomant is a specific gh antagonist developed for the treatment of acromegaly, and the basic molecule is gh with an amino acid substitution that blocks the conformational change necessary to generate functional ghr dimerization required for signal transduction. |
2004-10-07 |
2023-08-12 |
Not clear |
| Beate Karges, Roland Pfäffle, Bernhard O Boehm, Wolfram Karge. Acromegaly induced by growth hormone replacement therapy. Hormone research. vol 61. issue 4. 2004-10-06. PMID:14707471. |
this observation demonstrates that the indiscriminate use of recombinant gh bears the risk of active acromegaly, emphasizing the need for long-term patient monitoring programs as integral part of gh therapy. |
2004-10-06 |
2023-08-12 |
human |
| Shereen Ezza. Pharmacological approach to the treatment of acromegaly. Neurosurgical focus. vol 16. issue 4. 2004-10-04. PMID:15191332. |
somatostatin analogs, derived from the native inhibitory hormone somatostatin, are available in extended-duration preparations and are effective in reducing serum levels of growth hormone (gh) and insulin-like growth factor-i (igf-i) as well as in improving the adverse clinical effects of acromegaly. |
2004-10-04 |
2023-08-12 |
Not clear |
| Francesco Minuto, Eugenia Resmini, Mara Boschetti, Marica Arvigo, Maria Pia Sormani, Massimo Giusti, Diego Ferone, Antonina Barrec. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clinical endocrinology. vol 61. issue 1. 2004-09-27. PMID:15212656. |
assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous gh secretion and with the igf system. |
2004-09-27 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
random gh levels have been often used, but remain unreliable for the assessment of acromegaly. |
2004-08-30 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
mean gh levels are also frequently used to assess gh status, but are not specific for the diagnosis of acromegaly. |
2004-08-30 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
measurement of glucose suppressed gh levels is the preferred method for assessing gh secretion in acromegaly. |
2004-08-30 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
however, it is essential to recognize that when using highly sensitive and specific gh assays, nadir gh levels can be < 1 microg/l after oral glucose in some patients with newly diagnosed acromegaly and postoperative patients with active disease. |
2004-08-30 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
on the other hand, when using most clinically available commercial gh assays which are less sensitive and specific than those used in research studies, failure of gh suppression into the normal range set in these studies is not alone diagnostic of active acromegaly. |
2004-08-30 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
in order to diagnose acromegaly, documentation of gh excess should be accompanied by elevation in levels of the gh dependent peptide, insulin-like growth factor i (igf-i). |
2004-08-30 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
consideration also needs to be given to the clinical context in which gh and igf-i are being measured as both can be altered in a number of clinical settings other than acromegaly. |
2004-08-30 |
2023-08-12 |
Not clear |
| Pamela U Fred. Pitfalls in the biochemical assessment of acromegaly. Pituitary. vol 6. issue 3. 2004-08-30. PMID:14971738. |
both igf-i and gh evaluations are important and complimentary parts of the biochemical assessment of acromegaly. |
2004-08-30 |
2023-08-12 |
Not clear |
| F Minuto, A Barreca, G Meliol. Indirect evidence of hormone abuse. Proof of doping? Journal of endocrinological investigation. vol 26. issue 9. 2004-08-18. PMID:14964446. |
in conclusion, increases in igf-i, igfbp-3, als, piiip and ictp are all indicative of recent gh abuse or of acromegaly. |
2004-08-18 |
2023-08-12 |
human |
| A G Renehan, J O'Connell, D O'Halloran, F Shanahan, C S Potten, S T O'Dwyer, S M Shale. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 35. issue 11-12. 2004-08-16. PMID:14710350. |
acromegaly is an endocrine disorder characterised by sustained hypersecretion of growth hormone (gh) with concomitant elevation of insulin-like growth factor (igf)-i, and is associated with malignancy and premature mortality from cardiovascular and respiratory diseases. |
2004-08-16 |
2023-08-12 |
Not clear |
| Pamela U Freda, Carlos M Reyes, Abu T Nuruzzaman, Robert E Sundeen, Jeffrey N Bruc. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. vol 6. issue 4. 2004-07-27. PMID:15237928. |
basal and glucose-suppressed gh levels less than 1 microg/l in newly diagnosed acromegaly. |
2004-07-27 |
2023-08-12 |
human |
| Pamela U Freda, Carlos M Reyes, Abu T Nuruzzaman, Robert E Sundeen, Jeffrey N Bruc. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. vol 6. issue 4. 2004-07-27. PMID:15237928. |
the development of highly sensitive and specific gh assays has necessitated a critical re-evaluation of the biochemical criteria needed for the diagnosis of acromegaly. |
2004-07-27 |
2023-08-12 |
human |
| Pamela U Freda, Carlos M Reyes, Abu T Nuruzzaman, Robert E Sundeen, Jeffrey N Bruc. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. vol 6. issue 4. 2004-07-27. PMID:15237928. |
use of these assays has revealed that gh levels after oral glucose in healthy subjects and postoperative patients with active acromegaly can be significantly less than previously recognized with older gh assays. |
2004-07-27 |
2023-08-12 |
human |